Molecular Insight Pharmaceuticals, Inc. to Present Clinical, Preclinical Data at the Society of Nuclear Medicine 2009 Annual Meeting

CAMBRIDGE, MA - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) researchers will present data on the Company's progress in developing novel radiopharmaceuticals that may provide a promising option for molecular imaging of solid tumors, at the Society of Nuclear Medicine (SNM) annual meeting in Toronto. The presentations include clinical data on Molecular Insight's Trofex(TM), a radiolabeled, small-molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer. Trofex, an internally developed compound, targets prostate specific membrane antigen (PSMA), a protein highly expressed by prostate tumor cells, and has the potential to both detect and, when labeled with a therapeutic isotope, treat metastatic prostate cancer. Data also will be presented on Molecular Insight's recent discovery research oncology projects that have focused on the development of radiolabeled small-molecule inhibitors that target the cancer-related enzymes, carbonic anhydrase IX and seprase.